Breaking Finance News

JPMorgan downgraded Novavax (NASDAQ:NVAX) from Overweight to Neutral in a statement released earlier today.

Displaying a price of $8.34, Novavax (NASDAQ:NVAX) traded 0.36% higher on the day. With the last close up 33.70% relative to the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same period. The company has recorded a 50-day average of $7.35 and 200-day moving average of $6.24. Trading volume was was up over the average, with 25,965,663 shares of NVAX changing hands over the typical 5,016,980 shares.

JPMorgan has downgraded Novavax(NASDAQ:NVAX) from Overweight to Neutral in a report released 9/16/2016.

Previously on Tuesday August 23 2016, Vetr Inc. released a statement about Novavax(NASDAQ:NVAX) upped the target price from $0.00 to $8.66. At the time, this suggested an upside of 0.17%.

Performance Graphic:


Also covering Novavax’s price target, a total of 8 brokerages have reported on Novavax. The one year target is $15.39 with five analysts rating the stock a strong buy, three analysts rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and lastly 0 brokerages rating the stock as sell.

Novavax has a one-year low of $4.08 and a one-year high of $10.70. The company’s market cap is presently $0.0.

General Company Details For Novavax (NASDAQ:NVAX)

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *